Biocon Limited, a global biopharmaceutical company, released Yesafili (aflibercept-jbvf) in the United States. Yesafili is a biosimilar medicine same as Eylea 2 mg and is used to treat eye diseases. It works by blocking a protein called VEGF, which is linked to abnormal blood vessel growth in the eye. The U.S. Food and Drug Administration approved Yesafili in May 2024 as well as allowed it to be used as an interchangeable product according to state laws.
Around 19.8 million people in the United States have age-related macular degeneration (AMD), a major cause of permanent vision loss in people above 60 years old. The high demand for aflibercept treatments shows the demand for eye disease treatment effectively.
About Yesafili (aflibercept-jbvf):
Yesafili was approved after detailed laboratory, animal, as well as clinical studies showed that it is highly similar to Eylea 2 mg. In a Phase 3 clinical study called the INSIGHT Study, Yesafili was compared with Eylea 2 mg in patients with diabetic macular edema. The study showed that both medicines had similar safety, effectiveness, as well as patient response, with no important differences found.
According to Coherent Market Insights, the Biopharmaceutical and Biomedicine Market is projected to grow at a CAGR of 12.3% during 2026 to 2033. Currently, the market is at USD 719.01 Billion in 2026 and is expected to be around USD 1,619.55 Billion by 2033. Advancements in biomedical research have fueled the development of innovative therapeutic drugs as well as diagnostics. High investments by industry players and government organizations in R&D of novel biologics, cell, and gene therapies for the treatment of chronic diseases such as cancer and diabetes are also supporting market growth. The market is witnessing increasing adoption of personalized medicine aided by advancements in precision medicine and availability of patient specific data.
Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, “The launch of Yesafili™️ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea®️ 2 mg, advancing access to life-changing medicines for patients around the world.”
Source:
News: Biocon Limited
Company: Biocon Limited
